



PRAGUECZECH REPUBLIC

12-13 APRIL 2019

Co-Chairs Nicola Fazio, IT Gregory Kaltsas, GR





ESMO PRECEPTORSHIP PROGRAMME

GASTROENTEROPANCREATIC NEUROENDOCRINE NEOPLASMS

Multidisciplinary management, standards of care and future perspectives

Prague, Czech Republic 12-13 April 2019

CO-CHAIRS: Nicola Fazio, Italy

Gregory Kaltsas, Greece

SPEAKERS: Andrea Frilling, United Kingdom

Rocio Garcia-Carbonero, Spain

Massimo Milione, Italy Vikas Prasad, Germany

Christos Toumpanakis, United Kingdom

Marie-Pierre Vullierme, France

LEARNING OBJECTIVES

- Familiarise with the epidemiology, classification and prognostication of Gastroenteropancreatic (GEP) Neuroendocrine Neoplasms (NEN) patients
- Introduce principles of diagnostic and therapeutic strategy and the role of a multidisciplinary team
- Integrate different therapies in patients with advanced disease
- Familiarise with the genetic aberrations and their evolving role in diagnosis and treatment
- Update of new developments, clinical trials and unmet needs

ACCREDITATION

The programme of this event has been accredited with **9 ESMO-MORA category 1 points**.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details, please refer to esmo.org.

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from



ORGANISATION AND CONTACTS

ESMO Head Office Education Department Via Ginevra 4 6900 Lugano Switzerland

Email: courses@esmo.org

www.esmo.org



Friday, 12 April 2019

| 09:00-09:15 15' | Welcome and introduction | Nicola Fazio, IT Gregory Kaltsas, GR |
|--------------------|---|---|
| 09:15-10:50 95' | SESSION 1 Current evidence to diagnose and treat GEP-NENs patients | Chairs: Nicola Fazio, IT Gregory Kaltsas, GR |
| 15' | Pathologist (terminology and classifications) | Massimo Milione, IT |
| 15' | Radiologist | Marie-Pierre Vullierme, FR |
| 15' | Nuclear physician (theranostic role of nuclear medicine) | Vikas Prasad, DE |
| 10' | Q&A | Faculty |
| 10' | Gastroenterologist (role of endoscopy, chronic diarrhoea) | Christos Toumpanakis, UK |
| 10' | Endocrinologist (functioning pancreatic NETs) | Gregory Kaltsas, GR |
| 10' | Medical oncologist (metastatic disease) | Rocio Garcia-Carbonero, ES |
| 10' | Q&A | Faculty |

10:50-11:15 Coffee break

| 11:15-13:00 105' | SESSION 2 Multispecialist therapeutic approach | Chairs: Nicola Fazio, IT Gregory Kaltsas, GR |
|---------------------|--|---|
| 10' | Participant clinical case discussion | Faculty |
| 20' | Tumour board-like discussion | Nicola Fazio, IT |
| 10' | Molecular targeted agents in GEP NETs | Rocio Garcia-Carbonero, ES |
| 10' | Participant clinical case discussion | Faculty |
| 20' | Tumour board-like discussion | Gregory Kaltsas, GR |
| 10' | Locally advanced pancreatic NET management | Andrea Frilling, UK |
| 10' | Bases for Peptide Receptor Radionuclide Therapy (PRRT) in GEP NETs | Vikas Prasad, DE |
| 15' | Q&A | Faculty |

13:00-14:00 Lunch

| 14:00-15:30 90' | SESSION 3 Clinical syndromes | Chairs: Nicola Fazio, IT Gregory Kaltsas, GR |
|--------------------|--------------------------------------|---|
| 20' | Carcinoid syndrome | Christos Toumpanakis, UK |
| 10' | Participant clinical case discussion | Faculty |
| 20' | Tumour board-like discussion | Nicola Fazio, IT |
| 20' | Other clinical syndromes | Gregory Kaltsas, GR |
| 20' | Q&A | Faculty |

15:30-16:00 Coffee break

| 16:00-16:40 40' | SESSION 4 Tumour response assessment | Chairs: Nicola Fazio, IT Gregory Kaltsas, GR |
|--------------------|--|---|
| 10' | How to integrate morphological and functional imaging: Radiologist | Marie-Pierre Vullierme, FR |
| 10' | How to integrate morphological and functional imaging: Nuclear Physician | Vikas Prasad, DE |
| 10' | Radiological tumour response assessment | Marie-Pierre Vullierme, FR |
| 10' | Q&A | Faculty |

| 16:40-17:10 30' | | Chairs: Nicola Fazio, IT Gregory Kaltsas, GR |
|--------------------|--------------------------------------|---|
| 20' | Genetic syndromes: Clinical features | Gregory Kaltsas, GR |
| 10' | Somatostatin analogs | Nicola Fazio, IT |
| 19:30 | Dinner | |

Saturday, 13 April 2019

| 09:00-10:30 90' | SESSION 6 NEC and MANEC | Chairs: Nicola Fazio, IT Gregory Kaltsas, GR |
|--------------------|---|---|
| 10' | Mixed (neuroendocrine + non neuroendocrine) GEP neoplasms | Massimo Milione, IT |
| 20' | High grade GEP NENs medical treatments | Nicola Fazio, IT |
| 10' | Participant clinical case discussion | Faculty |
| 20' | Tumour board-like discussion | Nicola Fazio, IT |
| 10' | Participant clinical case discussion | Faculty |
| 20' | Tumour board-like discussion | Gregory Kaltsas, GR |

10:30-11:00 Coffee break

| 11:00-12:45 105' | SESSION 7 Toxicity management | Chairs: Nicola Fazio, IT Gregory Kaltsas, GR |
|---------------------|--|---|
| 10' | PRRT toxicity and safety | Vikas Prasad, DE |
| 10' | Endocrinological toxicity | Gregory Kaltsas, GR |
| 10' | Participant clinical case discussion | Faculty |
| 20' | Tumour board-like discussion | Nicola Fazio, IT |
| 10' | Chemotherapy and molecular targeted agents toxicity / safety | Rocio Garcia-Carbonero, ES |
| 30' | Summarising general approach to GEP NENs patients | Gregory Kaltsas, GR Nicola Fazio, IT |
| 15' | Q&A | Faculty |

| 12:45-13:00 15' | | Nicola Fazio, IT Gregory Kaltsas, GR |
|--------------------|-------|---|
| 13:00-14:00 | Lunch | |